Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Annals of Oncology

Volumn 29, Issue 1, 2018, Pages 250-255

  Pollack, M H ^a,b   Betof, A ^c   Dearden, H ^d   Rapazzo, K ^a,b   Valentine, I ^e   Brohl, A S ^e   Ancell, K K ^a,b   Long, G V ^d,f,g   Menzies, A M ^d,f,g   Eroglu, Z ^e   Johnson, D B ^a,b   Shoushtari, A N ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g Mater Hospital   (Australia)

Author keywords

Colitis; Immune related adverse events; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab

Indexed keywords

IMMUNOGLOBULIN; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLITIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYASTHENIA GRAVIS; NEPHRITIS; PANCREATITIS; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; STEROID THERAPY; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; UVEITIS; WHEEZING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; IMMUNOLOGY; MELANOMA; MULTICENTER STUDY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CTLA-4 ANTIGEN; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NIVOLUMAB; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES;

EID: 85041215859     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx642     Document Type: Article

References (15)

1. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
2. Long GV, Weber JS, Infante JR et al. Overall survival and durable responses in patients with braf v600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 2016; 34: 871-878.
3. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32(10): 1020-1030.
4. Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35(7): 785-792.
5. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33(18): 2092-2099.
6. Johnson DB, Balko JM, Compton ML et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375(18): 1749-1755.
7. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16(5): 522-530.
8. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372(21): 2006-2017.
9. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
10. Menzies AM, Johnson DB, Ramanujam S et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28(2): 368-376.
11. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
12. Weber JS, Kudchadkar RR, Gibney GT et al. Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. J Clin Oncol 2013; 31: 9011.
13. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521-2532.
14. Shoushtari AN, Friedman CF, Navid-Azarbaijani P et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 2017. [Epub ahead of print].
15. Long GV, Atkinson V, Cebon JS et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol 2017; 18(9): 1202-1210.